Phio Pharmaceuticals Corp. (PHIO)
Automate Your Wheel Strategy on PHIO
With Tiblio's Option Bot, you can configure your own wheel strategy including PHIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PHIO
- Rev/Share 0.0
- Book/Share 0.2825
- PB 8.388
- Debt/Equity 0.0
- CurrentRatio 10.5795
- ROIC -0.4261
- MktCap 11371616.0
- FreeCF/Share -0.1343
- PFCF -1.9654
- PE -15.0897
- Debt/Assets 0.0
- DivYield 0
- ROE -1.0565
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PHIO | H.C. Wainwright | -- | Buy | -- | $14 | June 5, 2025 |
News
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
Published: July 25, 2025 by: Newsfile Corp
Sentiment: Neutral
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise …
Read More
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Published: July 25, 2025 by: Newsfile Corp
Sentiment: Neutral
Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patient King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that pathologic results are available for four of the five patients treated in the fourth cohort.
Read More
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
Published: June 06, 2025 by: Newsfile Corp
Sentiment: Neutral
- Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds.
Read More
Best Value Stocks to Buy for May 28th
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.
Read More
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Published: May 19, 2025 by: Newsfile Corp
Sentiment: Neutral
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ET Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr.
Read More
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Published: May 07, 2025 by: Newsfile Corp
Sentiment: Neutral
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10th Marlborough, Massachusetts--(Newsfile Corp. - May 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (cSCC) treated …
Read More
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Published: May 01, 2025 by: Newsfile Corp
Sentiment: Neutral
Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr.
Read More
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
Read More
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
Published: April 03, 2025 by: Newsfile Corp
Sentiment: Neutral
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today announced that podium presentations will be given on its two lead INTASYL product candidates, PH-762 and PH-894.
Read More
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Published: February 26, 2025 by: Newsfile Corp
Sentiment: Neutral
Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr.
Read More
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
Published: February 20, 2025 by: Newsfile Corp
Sentiment: Neutral
Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr.
Read More
About Phio Pharmaceuticals Corp. (PHIO)
- IPO Date 2012-05-10
- Website https://www.phiopharma.com
- Industry Biotechnology
- CEO Robert J. Bitterman
- Employees 5